These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 9817971)
1. Tumour markers and their prognostic value in adenocarcinoma of the cervix. Ngan HY; Cheung AN; Lauder IJ; Cheng DK; Wong LC; Ma HK Tumour Biol; 1998; 19(6):439-44. PubMed ID: 9817971 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Avall-Lundqvist EH; Sjövall K; Nilsson BR; Eneroth PH Eur J Cancer; 1992; 28A(10):1695-702. PubMed ID: 1389488 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125. Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of serum tumour markers in carcinoma of the cervix. Ngan HY; Cheung AN; Lauder IJ; Wong LC; Ma HK Eur J Gynaecol Oncol; 1996; 17(6):512-7. PubMed ID: 8971531 [TBL] [Abstract][Full Text] [Related]
5. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. Sproston AR; Roberts SA; Davidson SE; Hunter RD; West CM Br J Cancer; 1995 Dec; 72(6):1536-40. PubMed ID: 8519673 [TBL] [Abstract][Full Text] [Related]
6. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tabata T; Takeshima N; Tanaka N; Hirai Y; Hasumi K Tumour Biol; 2000; 21(6):375-80. PubMed ID: 11006578 [TBL] [Abstract][Full Text] [Related]
7. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459 [TBL] [Abstract][Full Text] [Related]
8. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
9. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449 [TBL] [Abstract][Full Text] [Related]
10. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients. Kotowicz B; Kaminska J; Fuksiewicz M; Kowalska M; Jonska-Gmyrek J; Gawrychowski K; Sobotkowski J; Skrzypczak M; Starzewski J; Bidzinski M Int J Gynecol Cancer; 2010 May; 20(4):588-92. PubMed ID: 20686378 [TBL] [Abstract][Full Text] [Related]
12. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients. Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226 [TBL] [Abstract][Full Text] [Related]
13. Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. Yuan CC; Wang PH; Ng HT; Tsai LC; Juang CM; Chiu LM Eur J Gynaecol Oncol; 2002; 23(1):17-20. PubMed ID: 11876385 [TBL] [Abstract][Full Text] [Related]
14. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706 [TBL] [Abstract][Full Text] [Related]
15. Clinical implications of elevated pretreatment carcinoembryonic antigen in patients with advanced squamous cell carcinoma of the uterine cervix. Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Yang SN; Lin FJ Tumour Biol; 2008; 29(4):255-61. PubMed ID: 18781097 [TBL] [Abstract][Full Text] [Related]
16. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544 [TBL] [Abstract][Full Text] [Related]
17. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184 [TBL] [Abstract][Full Text] [Related]
18. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix. Ngan HY; Cheng GT; Yeung WS; Wong LC; Ma HK Gynecol Oncol; 1994 Jan; 52(1):63-8. PubMed ID: 8307503 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Niklinski J; Furman M; Laudanski J; Kozlowski M Eur J Cancer Prev; 1992 Oct; 1(6):401-6. PubMed ID: 1334443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]